After placing Algocyte instruments for testing and validation studies at leading hospitals in the UK, including Cambridge and King's College London — home to Algocyte's headquarters — Algocyte is entering a new chapter, expanding research studies internationally.
Algocyte's Mobile Health System (MHS) is a medical device capable of generating 15 immune-related markers alongside a complete blood count, the most widely performed laboratory test in clinical medicine. These international research deployments will significantly broaden the diversity and robustness of its validation data.
Taking the next step towards clinical validation and preparing for international regulatory approvals, Algocyte is now being deployed in the United Arab Emirates, Mexico and Canada, following agreements with major digital healthcare, population disease research and medical innovation partners.
The UK and local Algocyte teams attended meetings in Riyadh, Abu Dhabi and Dubai, including with a family office in Saudi Arabia and the leadership team of the Emirates Drug Establishment in Dubai.
In Canada, Algocyte is being deployed to the Virtual Healthcare Hub in Saskatchewan, a region characterised by vast geography and limited access to traditional brick-and-mortar healthcare facilities. The MHS device will be evaluated against conventional care pathways to assess its performance in remote monitoring scenarios, enabling patients to be monitored more closely within their own communities. A first device is being delivered to their facilities following loan agreements covering an initial batch of 100 tests. The Virtual Health Hub, supported by the Government and located approximately 35 km south of Saskatoon, operates as a centralised command centre delivering on-demand virtual care, remote patient monitoring and remote imaging diagnostic services to Saskatchewan communities entirely remotely.
In the United Arab Emirates, a pilot programme has been agreed with Burjeel Medical City under the support of the Department of Health to conduct an initial 150 tests. The Algocyte team trained medical staff during a morning session: nurses will carry the device to patients with blood disorders across Abu Dhabi, integrating it into existing clinical pathways and controlling for room temperature, a variable in the UAE to consider, while conducting comparative assessments. In parallel, nurses will train selected patients in self-testing and participate in structured usability studies to evaluate patient autonomy and real-world performance. Burjeel Medical City is the flagship hospital of Burjeel Holdings and one of the leading hospital networks in the region.
In Mexico, the national public health institute — equivalent to the U.S. CDC — will initiate an occupational medicine research study involving resident healthcare professionals. The study will focus on longitudinal monitoring and detection of disease patterns, with PCR confirmation of viral and bacterial infections to evaluate the longitudinal sensitivity and specificity of disease signature discovery. INER is a leading national medical research institute in Mexico, specialising in respiratory diseases and translational clinical research, and one of the earliest dedicated respiratory research institutes in the world, established before the U.S. CDC.
These studies will complement the current pilots by expanding the range of clinical indications and healthcare environments under evaluation, contributing to the growing body of evidence supporting Algocyte's role in early detection and precision health. In all settings, the goal is that oncology, infection and haematology users and patients benefit from simplified pathways to reduce disease severity, hospital visits and improve quality of life by strengthening health surveillance through remote and frequent monitoring.
Algocyte is the flagship solution of Oxford Immune Algorithmics, a deep-tech company spun out from Oxford University and King's College London that harnesses the power of beneficial AI to decentralise healthcare by integrating an ultra-portable blood-testing medical device with an AI-powered cloud platform to enable data-driven clinical monitoring, early detection and precision healthcare.